Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Nov;13(11):1720-4.
doi: 10.1023/a:1016457110726.

Applications and simulations of a discontinuous oral absorption pharmacokinetic model

Affiliations

Applications and simulations of a discontinuous oral absorption pharmacokinetic model

J W Witcher et al. Pharm Res. 1996 Nov.

Abstract

Purpose: To illustrate the application of a discontinuous oral absorption model to cimetidine and ranitidine plasma concentration versus time data to demonstrate the use of the model for drugs which display discontinuous oral absorption profiles, and to illustrate the effect of various model parameters on plasma drug concentration versus time profiles and bioavailability.

Methods: A discontinuous oral absorption model was used to fit ranitidine and cimetidine serum concentrations following oral and intravenous administration. The model was also used to simulate bioavailability and plasma concentrations versus time profiles for various parameter values.

Results: Serum concentrations following administration of ranitidine and cimetidine were well described by the model, and parameter estimates obtained were in agreement with literature values. Simulations demonstrate the effects of various absorption parameters and gastroin-testinal tract transit parameters on bioavailability and plasma concentration profiles.

Conclusions: This discontinuous oral absorption pharmacokinetic model can be a useful tool in characterizing absorption phases, disposition, and bioavailability of drugs exhibiting two absorption peaks following oral administration.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharm. 1983 Mar-Apr;2(2):157-62 - PubMed
    1. Clin Pharmacol Ther. 1983 Apr;33(4):445-52 - PubMed
    1. Pharm Res. 1995 Sep;12(9):1350-3 - PubMed
    1. Eur J Clin Pharmacol. 1984;26(2):197-207 - PubMed
    1. J Pharmacokinet Biopharm. 1987 Oct;15(5):529-44 - PubMed

Publication types

LinkOut - more resources